• Home
  • Search Results
  • Nitroglycerin: a review of its use in the treatment of vascular occlusion after soft tissue augmentation.

Nitroglycerin: a review of its use in the treatment of vascular occlusion after soft tissue augmentation.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (2012-12-05)
Kate Kleydman, Joel L Cohen, Ellen Marmur
ABSTRACT

Skin necrosis after soft tissue augmentation with dermal fillers is a rare but potentially severe complication. Nitroglycerin paste may be an important treatment option for dermal and epidermal ischemia in cosmetic surgery. To summarize the knowledge about nitroglycerin paste in cosmetic surgery and to understand its current use in the treatment of vascular compromise after soft tissue augmentation. To review the mechanism of action of nitroglycerin, examine its utility in the dermal vasculature in the setting of dermal filler-induced ischemia, and describe the facial anatomy danger zones in order to avoid vascular injury. A literature review was conducted to examine the mechanism of action of nitroglycerin, and a treatment algorithm was proposed from clinical observations to define strategies for impending facial necrosis after filler injection. Our experience with nitroglycerin paste and our review of the medical literature supports the use of nitroglycerin paste on the skin to help improve flow in the dermal vasculature because of its vasodilatory effect on small-caliber arterioles.

MATERIALS
Product Number
Brand
Product Description

Supelco
Trinitroglycerin solution, 1000 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Trinitroglycerin solution, 1 % (w/w) in propylene glycol, ampule of 1 mL, certified reference material, Cerilliant®

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.